WO2005087248A1 - 破骨細胞の分化及び/又は増殖に対する阻害作用を有する医薬 - Google Patents
破骨細胞の分化及び/又は増殖に対する阻害作用を有する医薬 Download PDFInfo
- Publication number
- WO2005087248A1 WO2005087248A1 PCT/JP2005/004512 JP2005004512W WO2005087248A1 WO 2005087248 A1 WO2005087248 A1 WO 2005087248A1 JP 2005004512 W JP2005004512 W JP 2005004512W WO 2005087248 A1 WO2005087248 A1 WO 2005087248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mushroom
- proliferation
- mushrooms
- food
- family
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a medicament comprising, as an active ingredient, a processed product of mushrooms having an inhibitory effect on osteoclast differentiation and Z or proliferation. Further, the present invention relates to a food containing the processed product of the above mushroom.
- Osteoporosis is a disease in which the bone mass of bone decreases and the trabecular bone disappears. Bone mass is controlled by the balance between the activity (proliferation) of osteoblasts that make bone and the activity (proliferation) of osteoclasts that break bone. The cycle between bone formation and bone resorption is called bone remodeling.
- Osteoclasts are giant cells that are derived from hematopoietic stem cells and are capable of monocyte / macrophage precursor cell differentiation. Although osteoclasts are involved in normal bone tissue development and remodeling, osteoclasts are important in pathologies such as bone loss in osteoporosis, osteoarticular destruction in rheumatoid arthritis, and bone metastasis of malignant tumors. It is known to play a role (Non-Patent Documents 1 and 2).
- Patent Document 2 soybeans and clover isoflavones and matillo extract as plant-derived substances
- Patent Document 1 Patent No. 1905330
- Patent Document 2 JP-A-2003-313137
- Non-patent document l Woodhouse, E.C., Cancer, 80 (8 Suppl), pp.1529-1537, 1997
- Non-patent document 2 Paleolog E.M., J. Rheumatol, 35, pp.917-919, 1996
- Non-Patent Document 3 Leung D.W., Science, 246, pp. 1306-1309, 1989
- Non-Patent Document 4 Goad D ⁇ ., Endocrinology, 137, pp.2262-2268, 1996
- Non-Patent Document 5 Gerber H.P., Nat.Med., 5, pp. 623-628, 1999
- Non-Patent Document 6 Niida S., J. Exp. Med., 190, pp. 293-298, 1999
- Non-patent document 7 Journal of Bone and Mineral Research, 15, pp. 1477-1488, 2000
- Non-patent document 8 Experimental Cell Research, 216, pp. 335-342, 1995
- Non-Patent Document 9 Biochemical Biophysical Research Communications, 264, pp.590-595, 1999
- An object of the present invention is to provide a medicament or food useful for preventing and / or treating bone loss in osteoporosis, prevention of bone joint destruction in rheumatoid arthritis, bone metastasis of malignant tumors, and the like. It is in. More specifically, it is an object of the present invention to provide a medicine or food containing, as an active ingredient, a substance having an inhibitory action on osteoclast cell division or proliferation. Further, it is an object of the present invention to provide a substance which has a function of inhibiting osteoclast cell division or proliferation and is highly safe. Is another object of the present invention.
- the present inventors have focused on mushrooms as foods having a long eating habit of obtaining highly safe substances in large quantities and at low cost. And we are conducting diligent research to solve the above problems. As a result, it was found that processed mushrooms such as pulverized mushrooms and mushroom extracts have an effect of inhibiting osteoclast differentiation or proliferation.
- the processed product of the mushrooms described above suppresses bone loss in osteoporosis, prevents or treats diseases associated with osteoclast differentiation or proliferation, such as bone and joint destruction in rheumatoid arthritis, or bone metastasis of malignant tumors.
- the present invention provides a medicine having an inhibitory effect on osteoclast differentiation and Z or proliferation, which comprises a processed product of mushrooms as an active ingredient. Further, the present invention provides a medicament for preventing and / or treating a disease involving osteoclast differentiation and / or Z or proliferation, wherein the medicament contains a processed product of mushrooms as an active ingredient.
- the mushroom is selected from the group consisting of tea mushrooms, matsutake mushrooms, and flat mushrooms, and the mushroom is a mushroom extract or a mushroom pulverized product. Medication is provided.
- the disease involving osteoclast cell division and Z or proliferation, osteoporosis, rheumatoid arthritis, and malignant tumor power are selected diseases, and suppression of bone loss in osteoporosis.
- the above-mentioned medicament used for prevention and / or treatment of osteoarticular destruction or bone metastasis of a malignant tumor in rheumatoid arthritis is also provided as a preferred embodiment.
- the use of the above processed mushroom for the manufacture of the above-mentioned medicament, and a method of inhibiting osteoclast differentiation and Z or proliferation in a mammal, including humans A method comprising administering a processed product of mushrooms to the animal; a method for preventing and / or treating a disease involving osteoclast differentiation and Z or proliferation;
- the invention provides a method comprising the step of administering to a mammal comprising:
- the present invention provides a food having an inhibitory effect on osteoclast differentiation and Z or proliferation, which contains a processed product of mushrooms as an active ingredient.
- a food having an inhibitory effect on osteoclast differentiation and Z or proliferation, which contains a processed product of mushrooms as an active ingredient.
- the mushrooms are selected from the group consisting of tea mushrooms, matsutake mushrooms, and flat mushrooms, and the processed food of mushrooms is a mushroom extract or a crushed mushroom Is done.
- the food in the form of food and drink is also included in the present invention. Provided by
- a food having an inhibitory effect on osteoclast differentiation and Z or proliferation comprising a processed product of mushrooms, which is used for osteoclast differentiation and Z or inhibition of proliferation.
- the food in the form of food and drink, the mushrooms are tea mushrooms, matsutake mushrooms, and mushroom powers. The above-mentioned food which is a crushed product of mushrooms is provided.
- the medicament of the present invention has an inhibitory effect on osteoclast differentiation and Z or proliferation, and is a disease involving osteoclast differentiation and Z or proliferation (eg, osteoporosis, chronic joint disease). It is useful as a medicament for the prevention and / or treatment of rheumatism or malignant tumors.
- the above-mentioned medicament can be used particularly for suppressing bone loss in osteoporosis, osteoarticular destruction in rheumatoid arthritis, or preventing and / or treating bone metastasis of malignant tumors.
- the food of the present invention has an inhibitory effect on the differentiation and Z or proliferation of upper osteoclasts, for example, suppression of bone loss in osteoporosis, osteoarticular destruction in rheumatoid arthritis, or bone metastasis of malignant tumor It can be used as a health food for the purpose of prevention and treatment of Z.
- FIG. 1 is a photograph showing the inhibitory activity of the medicament of the present invention on osteoclast cell division and Z or proliferation. Indicates the control state of RANKL (-).
- FIG. 2 is a photograph showing the inhibitory activity of the pharmaceutical agent of the present invention on osteoclast differentiation and Z or proliferation. The negative control state of RANKL (+) is shown.
- FIG. 3 is a photograph showing the inhibitory activity of the drug of the present invention on osteoclast differentiation and Z or proliferation. The action of an eryngii extract as a medicament of the present invention is shown.
- FIG. 4 is a transcript showing the inhibitory activity of the pharmaceutical of the present invention on osteoclast differentiation and Z or proliferation. Is true. 1 shows the action of a tea tree mushroom extract as a medicament of the present invention.
- FIG. 5 is a photograph showing the inhibitory activity of the pharmaceutical of the present invention on osteoclast differentiation and Z or proliferation. The action of Matsutake mushroom extract as a medicament of the present invention is shown.
- FIG. 6 is a photograph showing the inhibitory activity of the pharmaceutical agent of the present invention on osteoclast differentiation and Z or proliferation.
- Fig. 4 shows the action of the yamabushitake extract as a medicine of the present invention.
- the mushrooms that can be used for preparing a mushroom processed product that is an active ingredient of the medicament or food of the present invention are not particularly limited as long as they have an inhibitory effect on osteoclast differentiation and Z or proliferation.
- Agaricaceae Coprinaceae, Bolbitiaceae, Strophariaceae, Shir ortinariaceae, Crepidotaceae, Rhodophyllaceae, Paxillaceae, Gomphidiaceae, trobilomycetaceae, Boletaceae, Russulaceae, Aphyllophora, tha family lavanaceae, lavicoronaceae doo,
- Ramariaceae family Stereaceae family, Hymenochaetaceae family, Sparassiaaceae family, Orticiaceae family, fhelephoraceae family, Meruliaceae family, Fistulmaceae dough,
- Amanitaceae family Pluteaceae doo, Tricholomataceae family, Agaricaceae family, Coprmaceae family, Bolbitiaceae family, trophanaceae family, and ortmariaceae family, and repiaotaceae family,
- Rhodophyllaceae family Paxillaceae family, Gomphidiaceae family, StroDilomycetaceae family, Boletaceae family, Russulaceae family, antharellaceae family, omphaceae family, lavanaceae family, lavicoronaceae family, Ramanaceae family, Sparassiaaceae family, Thelepho ceae family
- Dacrymyceataceae DOO Sirobasiaiaceae family, Ustilaginaceae family, Yeniaceae family,
- Fungi of the family Bulgariaceae, Pezizaceae, Sarcosomataceae, Morcneilaceae, and Helvellaceae are known as edible fungi and are preferred for preparing the mushroom processed product used in the present invention.
- Tricholomataceae DOO Agancaceae, Opramaceae, Bolbitiaceae
- Fungi of the family Sarcosomataceae and Morchellaceae are known as medicinal, and these are also preferred for the preparation of the mushroom kafune used in the present invention.
- Pleurotaceae family 3 ⁇ 4cmzophyllaceae family, Amanitaceae family, Pluteaceae family,
- Tncholomatacsas r-Dou Agaricacsas, Opramcsas, Bolbitiacsas,
- mushrooms that are preferred as mushrooms to be used are those that have a strong inhibitory effect on osteoclast differentiation and Z or proliferation.
- mushrooms for example,
- Mushroom fruit bodies, mycelia, and fungal nuclei can be obtained from natural products, but can also be obtained by cultivation or tank culture.
- the “mushroom processed product” may be any one as long as it is obtained by mushrooming mushrooms.
- processing means that the mushrooms such as natural products or cultivated products or cultured products are subjected to some kind of processing such as heating, drying, crushing, or extraction. And should not be construed as limiting the term in any way.
- mushroom child A processed product prepared by crushing the body, mycelium, or sclerotium into a form that is easy to ingest, or a processed product such as a fruit body, a mycelium, or an extract extracted from the sclerotium can be used.
- Mushroom or its extractability A processed product obtained by isolating, purifying, or concentrating one or more substances that inhibit osteoclast cell division and Z or proliferation may be used. Further, the substance can be synthetically or biologically synthesized and used as a processed product of mushrooms.
- the extract is generally prepared by extracting mushrooms (including those obtained by drying or pulverizing fruit bodies, mycelia, or sclerotia as necessary) with an organic solvent or hot water.
- the organic solvent include hexane, chloroform, ethyl acetate, butanol, and the like.
- chloroform is used.
- the method for preparing the extract from mushrooms is not particularly limited.
- the cells may be crushed by enzymatic treatment or physical treatment by a conventional method, and then extracted using hot water or an organic solvent.
- the pulverized material can be generally prepared by pulverizing the dried mushrooms, if necessary, using a pulverizer, a homogenizer, a mill, or the like.
- the pulverized material includes ultrafine particles pulverized to several microns or less than 1 micron using a jet mill or the like.
- One or more substances selected from the group consisting of sugars, lipids, proteins, peptides, amino acids, fatty acids, organic acids, and salts are added to the processed mushrooms as necessary.
- the inhibitory effect on osteoclast differentiation and Z or proliferation can be stably exhibited.
- the medicament of the present invention has an inhibitory effect on osteoclast cell division and Z or proliferation. This effect can be easily confirmed by those skilled in the art by examining the direct effect on osteoclast activity in vitro.
- the medicament of the present invention can be used as a medicament for preventing and / or treating a disease involving osteoclast differentiation and / or Z or proliferation. Examples of the above diseases include osteoporosis, rheumatoid arthritis, and malignant tumors, but the diseases to which the medicament of the present invention is applied are not limited to these diseases. More specifically, the medicament of the present invention is preferably used as a medicament for inhibiting bone loss in osteoporosis, osteoarticular destruction in rheumatoid arthritis, or preventing or treating bone metastasis of malignant tumors.
- a processed product of mushrooms may be administered alone, but it has strong affinity for bone tissue. It is also possible to prepare and administer a pharmaceutical composition containing a compound, a protein, a peptide, or the like and a mushroom processed product, or a medicament containing an active ingredient in which these substances are combined with the mushroom processed product.
- a mushroom processed product derived from a plurality of mushrooms may be used in combination.
- a pharmaceutical composition When prepared as a pharmaceutical composition, one or more pharmaceutical additives (e.g., excipients, disintegrants, binders, lubricants, dispersants) Or perfume) can be used, and a pharmaceutical composition for oral administration such as a liquid preparation, a tablet, a granule, a powder, a capsule, a dry syrup, a chewable preparation and the like can be prepared by a conventional method.
- a pharmaceutical composition for parenteral administration such as an injection or a suppository, may be prepared by using a mushroom processed product in an appropriate form such as an extract!
- the dose of the medicament of the present invention is not particularly limited and can be appropriately selected depending on conditions such as the patient's weight, sex, and age, the purpose of prevention or treatment, and the type of the target disease. Usually, it is about 1 to 300 g, preferably about 50 to 100 g, more preferably about 2 to 30 g per day for an adult as a dried fruit body equivalent.
- the food provided by the present invention is a food having an inhibitory effect on osteoclast differentiation and Z or proliferation, and is characterized by containing a processed product of mushrooms as an active ingredient.
- the type of food of the present invention is not particularly limited, and for example, it is possible to mix an appropriate amount of mushroom syrup in health drinks, confectioneries, processed foods, and the like.
- the food of the present invention can be used as a health food for the purpose of suppressing bone loss and preventing osteoarticular destruction, the use of the food of the present invention is not limited to the above-mentioned purposes. Absent.
- Pleurotaceae eryngii has recently been cultivated in Japan and is easily available. To 20 g of the dried and ground eryngii was added 100 mL of black-mouthed form, and the mixture was extracted at room temperature for 2 hours with occasional stirring, and the extract obtained by filtration was evaporated to dryness under reduced pressure.
- Bolbitiaceae tea mushrooms are used as a food ingredient in the People's Republic of China to make imported products easier. Can be obtained. 100 mL of black-mouthed form was added to 20 g of the dried and ground tea mushrooms, extracted with stirring at room temperature for 2 hours with occasional stirring, and the extract obtained by filtration was dried under reduced pressure.
- Tricholomataceae pine mushrooms are used as ingredients for high-grade mushrooms, and domestic and imported products can be easily obtained.
- 100 ml of black-mouthed form was added to 20 g of the dried 'crushed matsutake mushroom, and extracted at room temperature for 2 hours with occasional stirring. The extract obtained by filtration was evaporated to dryness under reduced pressure.
- Hericiaceae belonging to the family bamboo mushroom is used as a food ingredient in Chinese cuisine in the People's Republic of China, and is recently cultivated in Japan and can be easily obtained.
- 100 mL of black-mouthed form was added, extracted at room temperature for 2 hours with occasional stirring, and the extract obtained by filtration was evaporated to dryness under reduced pressure.
- Non-Patent Document 6 Niida S "J. Exp. Med., 190, pp. 293). -298, 1999).
- the well may. this embodiment using ⁇ sales osteoclast culture kit, rat child Department Esutorojen receptor c DNA RIKEN gene bank (pUC- ER6, RDB No. 1376) was inserted gene Osteoclasts obtained by growing RAW264.7 cells induced in this manner in a medium containing G418 (600 ⁇ g / mL) were used.
- RAW264.7 cells transfected with ERa were transformed into phenol red-free 10% immobilized CD-FBS-a-MEM containing 100 U / mL penicillin and 100 ⁇ g / mL streptomycin.
- the cells were suspended in a culture medium, inoculated to a 48-well culture plate at a volume of 20000 cells, and cultured at 37 ° C. in 5% carbon dioxide gas in the presence of 100 ng / mL RANKL.
- 0.1% of mushroom extract (100 mg / mL) dissolved in DMSO was added to each culture and cultured.
- the yamabushitake extract was added at 1% and cultured. After 4 days, the medium was replaced.
- the medicament of the present invention has an inhibitory effect on osteoclast cell division and Z or proliferation, and is a disease involving osteoclast differentiation and Z or proliferation (for example, osteoporosis, rheumatoid arthritis, or Malignant tumors) and is useful as a drug for prevention or treatment
- the food of the present invention can be used as a health food for the purpose of suppressing bone loss.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511030A JPWO2005087248A1 (ja) | 2004-03-15 | 2005-03-15 | 破骨細胞の分化及び/又は増殖に対する阻害作用を有する医薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-114736 | 2004-03-15 | ||
JP2004114736 | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005087248A1 true WO2005087248A1 (ja) | 2005-09-22 |
Family
ID=34975330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004512 WO2005087248A1 (ja) | 2004-03-15 | 2005-03-15 | 破骨細胞の分化及び/又は増殖に対する阻害作用を有する医薬 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005087248A1 (ja) |
WO (1) | WO2005087248A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008019223A (ja) * | 2006-07-14 | 2008-01-31 | National Univ Corp Shizuoka Univ | 破骨細胞の分化・増殖阻害剤 |
JP2009050192A (ja) * | 2007-08-26 | 2009-03-12 | Mizushi Fujimoto | ハナビラタケの菌核を含有する食品 |
JP2010018563A (ja) * | 2008-07-11 | 2010-01-28 | Iwade Kingaku Kenkyusho:Kk | 新規化合物及び当該化合物を有効成分とする骨疾患の予防又は治療剤 |
JP2010538057A (ja) * | 2007-09-05 | 2010-12-09 | ソルジェント カンパニー | D−ピニトールを有効成分として含む骨代謝性疾患の予防または治療用組成物 |
WO2012021466A2 (en) * | 2010-08-10 | 2012-02-16 | Ocularpeutics, Llc | Use of extracts of pezizaceae in the prevention and/or treatment of senile cataracts |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002308777A (ja) * | 2001-04-09 | 2002-10-23 | Fujibio Co Ltd | 血管新生阻害作用を有する組成物 |
WO2004026239A2 (en) * | 2002-09-20 | 2004-04-01 | Momentum Pharmaceuticals | Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption |
JP2004277414A (ja) * | 2003-02-28 | 2004-10-07 | Chisso Corp | 食用キノコ由来のエストロゲン様活性物質 |
-
2005
- 2005-03-15 WO PCT/JP2005/004512 patent/WO2005087248A1/ja active Application Filing
- 2005-03-15 JP JP2006511030A patent/JPWO2005087248A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002308777A (ja) * | 2001-04-09 | 2002-10-23 | Fujibio Co Ltd | 血管新生阻害作用を有する組成物 |
WO2004026239A2 (en) * | 2002-09-20 | 2004-04-01 | Momentum Pharmaceuticals | Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption |
JP2004277414A (ja) * | 2003-02-28 | 2004-10-07 | Chisso Corp | 食用キノコ由来のエストロゲン様活性物質 |
Non-Patent Citations (2)
Title |
---|
HATA K. ET AL: "Shokuyo Kinoko ni Fukumareru Kosso Sosho Yobo Inshi "Kintake" kara Miidasareta Steroid Kagobutsu no Seiri Kassei", KAGAKU TO SEIBUTSU, vol. 41, no. 12, 2003, pages 776 - 777 * |
HATA K. ET AL: "Stimulative effects of (22E, 24R) -ergosta-7, 22-diene-3b, 5a, 6b-triol from fruiting bodies of Tricholoma auratum, on a mouse osteoblastic cell line, MC3T3-E1", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 25, no. 8, 2002, pages 1040 - 1044 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008019223A (ja) * | 2006-07-14 | 2008-01-31 | National Univ Corp Shizuoka Univ | 破骨細胞の分化・増殖阻害剤 |
JP2009050192A (ja) * | 2007-08-26 | 2009-03-12 | Mizushi Fujimoto | ハナビラタケの菌核を含有する食品 |
JP2010538057A (ja) * | 2007-09-05 | 2010-12-09 | ソルジェント カンパニー | D−ピニトールを有効成分として含む骨代謝性疾患の予防または治療用組成物 |
JP2010018563A (ja) * | 2008-07-11 | 2010-01-28 | Iwade Kingaku Kenkyusho:Kk | 新規化合物及び当該化合物を有効成分とする骨疾患の予防又は治療剤 |
WO2012021466A2 (en) * | 2010-08-10 | 2012-02-16 | Ocularpeutics, Llc | Use of extracts of pezizaceae in the prevention and/or treatment of senile cataracts |
WO2012021466A3 (en) * | 2010-08-10 | 2012-05-10 | Ocularpeutics, Llc | Use of extracts of pezizaceae in the prevention and/or treatment of senile cataracts |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005087248A1 (ja) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101809156B1 (ko) | 퓨코스테롤을 포함하는 근육 질환 예방, 개선 또는 치료용 또는 근 기능 개선용 조성물 | |
EP2474237B1 (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
Rattanachaikunsopon et al. | Bacteriostatic effect of flavonoids isolated from leaves of Psidium guajava on fish pathogens | |
KR100799116B1 (ko) | 코디세핀을 함유하는 비만 치료 및 예방제용 약학 조성물 | |
KR101851195B1 (ko) | 발효 뽕잎, 발효 뽕잎 추출물 및 이의 용도 | |
KR20170005632A (ko) | 뜰보리수 추출물을 포함하는 비만 또는 고지혈증의 예방 또는 치료용 조성물 | |
US20160095889A1 (en) | Composition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels | |
AU2020229728A1 (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica WiKim0103 | |
WO2005087248A1 (ja) | 破骨細胞の分化及び/又は増殖に対する阻害作用を有する医薬 | |
JP2016102111A (ja) | 補助化療薬品とされる医薬組成物その用途 | |
KR20210039961A (ko) | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 | |
KR101219650B1 (ko) | 옻의 무독화 방법 및 무독화 옻피 추출물의 용도 | |
KR20130047458A (ko) | Ppar 작용 조절 질환의 예방, 개선 또는 치료용 조성물 | |
KR101497109B1 (ko) | Ppar 작용 조절 질환의 예방, 개선 또는 치료용 조성물 | |
JP5502449B2 (ja) | 腸内フローラバランス改善剤及びその製造方法 | |
JP4721128B2 (ja) | 冬虫夏草新菌株 | |
JP4109572B2 (ja) | 冬虫夏草菌糸体の培養方法及び組成物 | |
JP2007254332A (ja) | 免疫調整作用のあるメロン抽出物含有組成物 | |
KR102372440B1 (ko) | 비쑥 추출물을 유효성분으로 포함하는 골대사성 질환으로 유발된 골소실 예방 또는 치료용 약제학적 조성물 | |
KR101683030B1 (ko) | 발효 울금 추출물의 제조방법 및 이의 추출방법에 의해 얻어진 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
KR101618503B1 (ko) | 신규 지의류 내생 곰팡이 및 이의 추출물을 유효성분으로 포함하는 위암 또는 대장암의 예방 또는 치료용 조성물 | |
KR102244732B1 (ko) | 프로바이오틱 초산균인 아세토박터 파스테리아누스 mglv 및 이의 면역조절 효과 | |
KR101418164B1 (ko) | 자외선을 처리한 벼 추출물을 유효성분으로 포함하는 대장암 예방 또는 치료용 약학적 조성물 | |
KR20210146590A (ko) | 사간 추출물을 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 | |
CN101291679A (zh) | 包含猕猴桃属植物的组合物及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511030 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |